[Clinical and immunological characteristics and specific features of the treatment of patients with recurrent sarcoidosis of respiratory organs].
Kostina. Z I ZI; Brazhenko. N A NA; Gerasimova. E V EV; Alekseev. D Iu DIu; Kol'nikova. O V OV; Balashova. N M NM; Nasorina. R N RN
Key Findings
- Recurrence of sarcoidosis occurred in about 12% of patients, with moderate symptoms and reduced T‑cell numbers.
- Patients showed poor adaptive immune responses, with high immune complexes and immunoglobulins.
- Adding thymalin and other adaptogens improved treatment efficiency, reduced duration, and enhanced prognosis.
Practical Outcomes
- Thymalin may act as an immune‑supporting adaptogen, potentially useful for people seeking to strengthen adaptive immunity. However, evidence is confined to sarcoidosis patients, so broader claims for longevity or general health need more research before practical protocols can be recommended.
Summary
The study looked at many sarcoidosis patients and found that those with recurring lung disease had low T‑cell counts and high immune complexes, indicating weak immune responses. Adding the peptide thymalin (along with other adaptogens) seemed to boost the immune system, shorten treatment, and improve outcomes, but the research is limited to a specific disease group.
Abstract
In the past 35 years, the authors have followed up 5600 patients with sarcoidosis of respiratory organs (SRO), among whom 1.2 and 10.7% were found to have single and multiple recurrences. The clinical manifestations of recurrent sarcoidosis were moderate, by showing a drastic reduction in the count of T and T"a" lymphocytes, as well as helper lymphocytes, and an increase of circulating immune complexes and immunoglobulins G, A, and M. Poor adaptive responses (AR) defined by the blood leukocyte and lymphocyte counts that reflect the body's nonspecific responsiveness were concurrently diagnosed. In chronic recurrent SRO, poor AR as stress and superactivation amount to as much as 86.1%. To optimize treatment, the patients were given adaptogens (thymaline, levamisole, dibasole, etc.) that make AR better, by enhancing the efficiency of treatment, reducing its duration, and improving prognosis.
Study Information
pubmed
2001